Clinical Trial Update: Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety and immunogenicity of DNA vaccines expressing HIV Gag elements, administered with IL-12 DNA, in HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• IL-12 pDNA
• pDNA vaccines expressing HIV M Group p24^Gag conserved elements and/or p55^Gag

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2021-10-14